Avanir Pharmaceuticals Message Board

weekend! NUEDEXTA is on the way; and NOT just 1 dose strength, but 2 dose strengths!

(CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause. In addition, the CHMP also recommended approval of two dose strengths of NUEDEXTA; 20/10 mg and 30/10 mg capsules.

Sentiment: Strong Buy

pertaining to Avanir and Nuedexta! Ray, in fact makes it a point to disprove or attempt to point out inaccuracies based on Ray's scientific medical financial background. It's rather fun and humorous reading Ray's bashing comments.... Ray's favorite tag line is "I am waiting for off-label pain..." Oh, and Ray has a very small ownership interest in Avanir, as Ray previously pointed out! Who posts 20 or more times a day when one has a "small ownership" interest? Not sure!

Ray, you are either very bored, a former disgruntled employee, or a paid basher! Which one is it?

Ray, it's very clear you have an agenda!

Cheers

Sentiment: Strong Buy

Vivus is a favorite of yours! Vivus reported $4.1 millions in quarterly sales. Yet, the Vivus CEO made $1.2 million in salary, and exercised $8.3 million in stock! Perhaps you ought to bring your overpaid thesis to the Vivus message board. Again, you are on the WRONG message board! How about that MNKD, $1.8 billion market cap and $0 sales. Perhaps you ought to also bring your overpriced thesis to the MannKind message board. Cheers

"Greatday's function here seems to be as the "mouthpiece" of Avanir's CEO
Apparently if rankles Greatday if someone expresses the opinion that the CEO is overpaid, given Avanir's size and given the CEO's hypesterism and poor vision with regard to the pain program and with regard to hyping agitation in dementia when he didn't even have adaquate evidence to launch a study, much less to try to cover up that there is not a good scientific basis for doing the study by foolishly claiming there is "very strong proof of concept" for it."

Vivus
Mr. Leland F. Wilson , 69
Chief Exec. Officer and Director $1.16M salary 8.32M exercised options

Vivus... three months of the year, the company reported $4.1 M in sales

Sentiment: Strong Buy

Page 5 A

Receptor pharmacology reviewed below suggests a somewhat greater possibility of finding efficacy with high-dose dextromethorphan, however tolerability and plasma level variations make this somewhat more difficult to study than trials of conventional doses of Nuedexta. Specifically enumerated hypotheses based on the review of evidence (below) and these two pragmatic approaches are:
1. Dextromethorphan exhibits rapid-acting antidepressant efficacy in major depressive disorder.
2. Dextromethorphan exhibits conventional antidepressant efficacy in major depressive disorder.
3. Dextromethorphan exhibits antidepressant efficacy for treatment- refractory major depressive disorder.
4. Nuedexta exhibits rapid-acting antidepressant efficacy in major depressive disorder.
5. Nuedexta exhibits conventional antidepressant efficacy in major depressive disorder.
6. Nuedexta exhibits antidepressant efficacy for treatment-refractory major depressive disorde

Sentiment: Strong Buy

"The CEO has gotten plenty of "salaried income" and plenty in bonus money over the last few years and has sold much more than a million dollars of stock already on top of all that salary and bonus.
Unless he is living an ultra-lavish lifestyle, there should have been no compelling financial reason for him to sell all those shares."

Ray, tell that to Bill Gates; he works for Microsoft:

24-Apr-13 6,716,519 MSFT Automatic Sale at $31.11 - $31.72 per share.
(Proceeds of about $210,999,000)
23-Apr-13 5,888,974 MSFT Automatic Sale at $30.71 per share.
(Proceeds of $180,850,391)
22-Apr-13 7,394,507 MSFT Automatic Sale at $30.92 per share.
(Proceeds of $228,638,156)
6-Feb-13 3,189,267 MSFT Automatic Sale at $27.44 per share.
(Proceeds of $87,513,486)
5-Feb-13 3,810,733 MSFT Automatic Sale at $27.56 per share.
(Proceeds of $105,023,801)
4-Feb-13 3,000,000 MSFT Automatic Sale at $27.64 per share.
(Proceeds of $82,920,000)
1-Feb-13 5,500,000 MSFT Automatic Sale at $27.87 per share.
(Proceeds of $153,285,000)
31-Jan-13 4,500,000 MSFT Automatic Sale at $27.50 per share.
(Proceeds of $123,750,000)
31-Jan-13 1,366 MSFT Acquisition (Non Open Market) at $0 per share.
27-Nov-12 1,384 MSFT Acquisition (Non Open Market) at $0 per share.
25-Oct-12 5,500,000 MSFT Automatic Sale at $27.95 per share.
(Proceeds of $153,725,000)
24-Oct-12 4,500,000 MSFT Automatic Sale at $28.03 per share.
(Proceeds of $126,135,000)
23-Oct-12 5,500,000 MSFT Automatic Sale at $28.06 per share.
(Proceeds of $154,330,000)
22-Oct-12 4,500,000 MSFT Automatic Sale at $28.02 per share.
(Proceeds of $126,090,000)
15-Aug-12 1,242 MSFT Acquisition (Non Open Market) at $0 per share.
27-Jul-12 5,000,000 MSFT Automatic Sale at $29.57 per share.
(Proceeds of $147,850,000)
26-Jul-12 5,000,000 MSFT Automatic Sale at $29.24 per share.
(Proceeds of $146,200,000)
25-Jul-12 3,000,000 MSFT Automatic Sale at $28.99 per share.
(Proceeds of $86,970,000)
24-Jul-12 2,750,000 MSFT Automatic Sale at $29.09 per share

Sentiment: Strong Buy

holiday weekend!

Sentiment: Strong Buy

Memorial Day Weekend!

Sentiment: Strong Buy

Listen and be informed!

Jefferies 2013 Global Healthcare Conference
Presentation date: Wednesday June 5, 2013
Presentation time: 8:30 a.m. E.T.

Sentiment: Strong Buy

Note Depression!

Broad potential with follow-on indications

Pain: MS Pain, DPN pain, many others

Mood/Behavior: Agitation in AD, autism, DEPRESSION

Movement Disorder: Dyskinesia, Chorea, spasticity

Sentiment: Strong Buy

Avanir!

Sentiment: Strong Buy